标题
Antibodies to watch in 2022
作者
关键词
-
出版物
mAbs
Volume 14, Issue 1, Pages -
出版商
Informa UK Limited
发表日期
2022-01-15
DOI
10.1080/19420862.2021.2014296
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Efficacy, Safety, and Correlative Biomarkers of Toripalimab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial (POLARIS-02)
- (2021) Feng-Hua Wang et al. JOURNAL OF CLINICAL ONCOLOGY
- Zanidatamab (ZW25) in HER2-positive biliary tract cancers (BTCs): Results from a phase I study.
- (2021) Funda Meric-Bernstam et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy and safety of geptanolimab (GB226) for relapsed or refractory peripheral T cell lymphoma: an open-label phase 2 study (Gxplore-002)
- (2021) Yuankai Shi et al. Journal of Hematology & Oncology
- Antibodies to watch in 2021
- (2021) Hélène Kaplon et al. mAbs
- Cross-linking of T cell to B cell lymphoma by the T cell bispecific antibody CD20-TCB induces IFNγ/CXCL10-dependent peripheral T cell recruitment in humanized murine model
- (2021) Floriana Cremasco et al. PLoS One
- A therapeutic neutralizing antibody targeting receptor binding domain of SARS-CoV-2 spike protein
- (2021) Cheolmin Kim et al. Nature Communications
- FAST: A randomised phase II study of zolbetuximab (IMAB362) plus EOX vs EOX alone for first-line treatment of advanced CLDN18.2 positive gastric and gastro-oesophageal adenocarcinoma
- (2021) U. Sahin et al. ANNALS OF ONCOLOGY
- Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial
- (2021) Kristian Reich et al. LANCET
- Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial
- (2021) Kenneth B Gordon et al. LANCET
- Donanemab in Early Alzheimer’s Disease
- (2021) Mark A. Mintun et al. NEW ENGLAND JOURNAL OF MEDICINE
- A BCMAxCD3 bispecific T cell–engaging antibody demonstrates robust antitumor efficacy similar to that of anti-BCMA CAR T cells
- (2021) David J. DiLillo et al. Blood Advances
- Discovery of amivantamab (JNJ-61186372), a bispecific antibody targeting EGFR and MET
- (2021) Joost Neijssen et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell–Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial
- (2021) Martin Hutchings et al. JOURNAL OF CLINICAL ONCOLOGY
- Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial
- (2021) Paolo F Caimi et al. LANCET ONCOLOGY
- FDA approves 100th monoclonal antibody product
- (2021) Asher Mullard NATURE REVIEWS DRUG DISCOVERY
- Sutimlimab in Cold Agglutinin Disease
- (2021) Alexander Röth et al. NEW ENGLAND JOURNAL OF MEDICINE
- Bimekizumab versus Adalimumab in Plaque Psoriasis
- (2021) Richard B. Warren et al. NEW ENGLAND JOURNAL OF MEDICINE
- Bimekizumab versus Secukinumab in Plaque Psoriasis
- (2021) Kristian Reich et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma
- (2021) Andrew Menzies-Gow et al. NEW ENGLAND JOURNAL OF MEDICINE
- A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody
- (2021) Chad J. Swanson et al. Alzheimers Research & Therapy
- Study protocol of the global Effisayil 1 Phase II, multicentre, randomised, double-blind, placebo-controlled trial of spesolimab in patients with generalized pustular psoriasis presenting with an acute flare
- (2021) Siew Eng Choon et al. BMJ Open
- Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non–Small-Cell Lung Cancer
- (2021) Jie Wang et al. JAMA Oncology
- Therapeutic effect of CT-P59 against SARS-CoV-2 South African variant
- (2021) Dong-Kyun Ryu et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Generalized Pustular Psoriasis: Divergence of Innate and Adaptive Immunity
- (2021) Dominik Samotij et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Efficacy and safety of HLX10, a novel anti-PD-1 antibody, in patients with previously treated unresectable or metastatic microsatellite instability-high or mismatch repair-deficient solid tumors: A single-arm, multicenter, phase 2 study.
- (2021) Shukui Qin et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase 2, open-label, multicenter study to evaluate the efficacy, safety, and tolerability of KN046 in combination with chemotherapy in subjects with advanced non-small cell lung cancer.
- (2021) Yunpeng Yang et al. JOURNAL OF CLINICAL ONCOLOGY
- Promising tolerability and efficacy results from dose-escalation in an ongoing phase Ib/II study of mosunetuzumab (M) with polatuzumab vedotin (Pola) in patients (pts) with relapsed/refractory (R/R) B-cell non-Hodgkin’s lymphoma (B-NHL).
- (2021) L Elizabeth Budde et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase II study of penpulimab, an anti-PD-1 antibody, in patients with relapsed or refractoryclassic Hodgkin lymphoma (cHL).
- (2021) Yuqin Song et al. JOURNAL OF CLINICAL ONCOLOGY
- Mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients (pts) with platinum-agnostic ovarian cancer: Final analysis.
- (2021) David M. O'Malley et al. JOURNAL OF CLINICAL ONCOLOGY
- RATIONALE 302: Randomized, phase 3 study of tislelizumab versus chemotherapy as second-line treatment for advanced unresectable/metastatic esophageal squamous cell carcinoma.
- (2021) Lin Shen et al. JOURNAL OF CLINICAL ONCOLOGY
- Updated results of a phase 1, first-in-human study of talquetamab, a G protein-coupled receptor family C group 5 member D (GPRC5D) × CD3 bispecific antibody, in relapsed/refractory multiple myeloma (MM).
- (2021) Jesus G. Berdeja et al. JOURNAL OF CLINICAL ONCOLOGY
- Relatlimab (RELA) plus nivolumab (NIVO) versus NIVO in first-line advanced melanoma: Primary phase III results from RELATIVITY-047 (CA224-047).
- (2021) Evan J. Lipson et al. JOURNAL OF CLINICAL ONCOLOGY
- Subcutaneous envafolimab monotherapy in patients with advanced defective mismatch repair/microsatellite instability high solid tumors
- (2021) Jian Li et al. Journal of Hematology & Oncology
- Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study
- (2021) Saad Z Usmani et al. LANCET
- Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial
- (2021) Hai-Qiang Mai et al. NATURE MEDICINE
- A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer’s disease
- (2021) Stephen Salloway et al. NATURE MEDICINE
- Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19
- (2021) Michael Dougan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab
- (2021) Anil Gupta et al. NEW ENGLAND JOURNAL OF MEDICINE
- A phase II study of efficacy and safety of RC48-ADC in patients with locally advanced or metastatic HER2-overexpressing gastric or gastroesophageal junction cancers.
- (2020) Zhi Peng et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy and safety of sintilimab plus pemetrexed and platinum as first-line treatment for locally advanced or metastatic nonsquamous non-small cell lung cancer: a randomized, double-blind, phase 3 study (ORIENT-11)
- (2020) Yunpeng Yang et al. Journal of Thoracic Oncology
- 1419TiP ARC-7: A phase II study to evaluate the safety and efficacy of zimberelimab alone, AB154 in combination with zimberelimab, and AB154 in combination with zimberelimab and AB928 in front-line, PD-L1 expressing, non-small cell lung cancer (NSCLC)
- (2020) A. Chaudhry et al. ANNALS OF ONCOLOGY
- Tislelizumab in Asian patients with previously treated locally advanced or metastatic urothelial carcinoma
- (2020) Dingwei Ye et al. CANCER SCIENCE
- A Phase 2/3 Trial of Pabinafusp Alfa, IDS Fused with Anti-Human Transferrin Receptor Antibody, Targeting Neurodegeneration in MPS-II
- (2020) Torayuki Okuyama et al. MOLECULAR THERAPY
- Sintilimab: A Promising Anti-Tumor PD-1 Antibody
- (2020) Lin Zhang et al. Frontiers in Oncology
- GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells
- (2019) Eric L. Smith et al. Science Translational Medicine
- Tebentafusp: T Cell Redirection for the Treatment of Metastatic Uveal Melanoma
- (2019) Bertil E. Damato et al. Cancers
- Insights into the IgG heavy chain engineering patent landscape as applied to IgG4 antibody development
- (2019) Christophe Dumet et al. mAbs
- TIGIT as an emerging immune checkpoint
- (2019) H. Harjunpää et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- Phase I study of chimeric anti-CD20 monoclonal antibody in Chinese patients with CD20-positive non-Hodgkin’s lymphoma
- (2016) Lin Gui et al. Chinese Journal of Cancer Research
- Antibodies to watch in 2010
- (2010) Janice M. Reichert mAbs
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now